Living Longer, Living “Better”: A Clinical Pharmacist’s Look at Transhumanism, Longevity Drugs, and the Pharmaceutical Horizon
- Dr. Alexandra LaStella, PharmD, RPh
- Jun 18
- 6 min read
Updated: Jun 18
ORCiD# 0009-0006-4779-9915
Introduction
Transhumanism is a philosophy and social movement that advocates for using advanced science and technology to enhance human capabilities—particularly in extending lifespan, improving cognition, and refining physical appearance. While its theoretical roots stretch back decades, transhumanism has gained significant momentum recently, fueled by cutting-edge biotech, major tech investment, and a surge of clinical research into aging-related interventions. As pharmacists, it's essential to evaluate which of these enhancements are nearing clinical application, to assess their pharmacologic rationale, and to anticipate where ethical and safety concerns may arise in caring for patient populations.
The Biological Drive Behind Transhumanism
A common goal within transhumanist thinking is not just a longer life, but a longer healthspan—that portion of life spent free from chronic illness and functional decline. Researchers in bio-gerontology believe that targeting the cellular and molecular hallmarks of aging—such as impaired autophagy, senescent cell accumulation, and metabolic dysregulation—could achieve this goal. Medications targeting key pathways like AMPK (activated by metformin), mTOR (inhibited by rapalogs), NAD+ metabolism, and senescent cell clearance are emerging as candidates for "enhanced" health. Although early clinical trials show encouraging signals, mainstream acceptance remains cautious: regulatory approval is typically granted for treating diseases, not for delaying aging, pushing longevity drugs into off-label or investigational categories.
Metformin and the Quest for Healthy Longevity
Metformin, a well-established antidiabetic agent, has attracted attention for its potential longevity benefits. By activating AMPK, metformin mimics the effects of caloric restriction—a well-known lifespan-extending intervention in animal models. Retrospective studies suggest that diabetic patients on metformin live longer than both untreated diabetics and age-matched non-diabetic controls, with fewer age-related illnesses¹. The ongoing TAME (Targeting Aging with Metformin) trial marks a significant milestone, as it directly evaluates whether metformin can delay the onset of multiple age-related diseases in non-diabetic older adults. While this could redefine the boundaries between disease treatment and aging intervention, widespread use hinges on positive outcomes, well-defined dosing, and thorough safety evaluation in non-diabetic populations. Gastrointestinal upset remains a common side effect and may limit long-term compliance outside of diabetes treatment.
The Rise of Rapamycin and Its 'Rapalogues'
mTOR, a central regulator of cell growth and aging, is another target in the pharmacologic longevity toolbox. Rapamycin and its analogues (rapalogs) suppress mTORC1 signaling, triggering cellular processes like autophagy and stress resistance. Early human studies have shown that topical rapamycin can reverse markers of skin aging and that oral rapamycin enhances certain immune responses in older adults. In mouse models, intermittent rapamycin dosing has extended lifespan and delayed multiple age-related pathologies. However, immunosuppression and metabolic side effects—such as mouth ulcers, dyslipidemia, and elevated blood sugars—raise concerns, especially when used chronically. Long-term safety data are lacking, and the risk-benefit balance will be critical if these agents are to transition beyond immunology and oncology into preventive health use.
Senolytics: The First Wave of Cellular Rejuvenation Medicine
Senolytics, a novel class of medications including dasatinib, quercetin, and fisetin, aim to selectively eliminate senescent cells implicated in aging-related tissue dysfunction. Early-phase trials in humans—particularly those using dasatinib plus quercetin in diabetic kidney disease—have reported reductions in senescent cell markers and modest functional improvements. While the targeted mechanism is scientifically compelling, clinical expansion faces drug safety barriers: dasatinib carries risk of serious hematologic side effects, and natural compounds like quercetin may alter metabolism of co-administered drugs. Additionally, senolytic treatment regimens remain empirical; there is no standardized schedule, dose, or set of biomarkers to monitor response in healthy people.
NAD⁺ Precursors: Boosting Cellular Energy Pools
Declining levels of NAD⁺, a coenzyme essential for mitochondrial function and DNA repair, are believed to contribute to aging and cellular breakdown. Oral supplementation with nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) has demonstrated increased NAD⁺ levels in humans and improvements in markers of inflammation and mitochondrial health in preliminary studies. These compounds are sold widely as supplements, though their regulatory status remains ambiguous—NMN has even received a warning letter from FDA for being marketed as an unapproved drug. Though generally well tolerated, their long-term safety, effects on methylation pathways, and true impact on healthspan remain under investigation.
Peptide Hormones and the Search for Rejuvenation
Hormonal therapies, such as growth hormone secretagogues, thymic peptides, and androgenic modulators, are also being studied for their potential to rejuvenate tissue and reverse biological aging. The small TRIIM study, for example, reported thymus regeneration and immune improvements with a combination of growth hormone, DHEA, and metformin. However, these approaches raise concerns around pro-growth and pro-cancer pathways, as well as metabolic and fluid-related side effects. Evidence remains in the preliminary stage, and ethical issues around "designer" hormone stacks continue to emerge.
Genetic and Epigenetic Resetting
The intersection of transhumanism with genetic editing and epigenetic reprogramming tools like CRISPR and OSKM exposes both profound promise and profound uncertainty. Preclinical research has restored vision in aged mice and significantly reversed molecular markers of aging through targeted gene reprogramming. While early human gene therapy efforts are underway in conditions like sickle cell disease and muscular dystrophy, using these approaches for enhancement—as opposed to treating disease—raises intricate ethical, safety, and social questions that remain unresolved.
Big Pharma, Regulation, and the Ethics of Enhancement
Pharmaceutical industry interest in longevity and anti-aging therapeutics has surged, with projected market valuations exceeding $60 billion by 2030. Yet regulatory frameworks have not kept pace: aging itself is not considered a treatable condition by any major regulatory agency. Consequently, companies must pursue labelling in diseases such as Alzheimer’s, osteoporosis, or sarcopenia instead of aging. This regulatory workaround may delay the influx of longer-term aging interventions, but interest remains high—both from biotech startups and large pharmaceutical firms positioning for secondary label expansion.
Balancing Potential Rewards with Ethical Concerns
Pharmacologic advances in transhumanist goals could compress morbidity, reducing the duration of illness in old age and potentially saving on healthcare costs. Preventative approaches aimed at upstream hallmarks may be more efficient than disease-by-disease management. However, these therapies also bring substantial risks: long-term safety remains unknown; treatments may exacerbate socioeconomic disparities; unregulated use of experimental compounds raises safety and ethical issues; and society may see increased pressure toward appearance-based standards that pathologize normal aging.
Implications for Clinical Pharmacy Practice
From a clinical pharmacist’s viewpoint, the rise of transhumanist drug interventions represents both opportunity and responsibility. Where evidence exists, such as with metformin in pre-diabetic populations, pharmacists can support responsible use. However, OTC and compounded agents—including rapalogs, senolytics, and peptides—may emerge in patients’ regimens with minimal oversight, raising safety and interaction concerns. It will become imperative to screen for immunosuppression, endocrinologic imbalances, or CYP-involved interactions, and to counsel patients with transparency about the still-emerging evidence base. Reporting unexpected adverse events is equally essential to building collective knowledge as these therapies proliferate outside regulated trials.
Conclusion
As a clinical pharmacist, I see pharmacologic transhumanism standing at a critical crossroads. Early data offer hope for extending healthy life and improving quality of life, but these advances must be weighed against safety, equity, and ethical considerations. Only through rigorous clinical trials, careful patient selection, and ongoing pharmacovigilance can we responsibly bring these technologies into practice. Tomorrow’s pharmacist may indeed dispense senolytics, rapalogs, or NAD⁺ boosters—but only if today’s research remains as comprehensive and cautious as the ambitions behind transhumanism itself.
Resources
Bostrom N. A history of transhumanist thought. Journal of Evolution and Technology. 2005;14(1). Accessed June 18, 2025. https://nickbostrom.com/papers/a-history-of-transhumanist-thought/?utm_source=chatgpt.com
Mohammed I, Hollenberg MD, Ding H, Triggle CR. A critical review of the evidence that metformin is a putative anti‑aging drug that enhances healthspan and extends lifespan. Frontiers in Endocrinology. 2021;12:718942. doi:10.3389/fendo.2021.718942
Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048‑8067. doi:10.18632/aging.102355
Chung CL, Lawrence I, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41:861‑869. doi: 10.1007/s11357‑019‑00113‑y
Hickson LJ, Prata LG, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446‑456. doi:10.1016/j.ebiom.2019.08.069
Martens CR, Denman BA, et al. Chronic nicotinamide riboside supplementation is well‑tolerated and elevates NAD⁺ in healthy middle‑aged and older adults. Nature Communications. 2018;9(1):1286. doi:10.1038/s41467‑018‑03421‑7
Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell. 2019;18(6):e13028. doi:10.1111/acel.13028
Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124‑129. doi:10.1038/s41586‑020‑2975‑4
Grand View Research. Anti‑aging therapeutics market size report, 2024‑2030. Published 2024. Accessed June 18, 2025. https://www.grandviewresearch.com/industry-analysis/anti-aging-therapeutics-market
